Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 7,605 full-time employees. The firm is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. The company operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). The company is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. The company also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).
Follow-Up Questions
What is Biogen Inc (BIIB)'s P/E Ratio?
The P/E ratio of Biogen Inc is 12.9173
Who is the CEO of Biogen Inc?
Mr. Christopher Viehbacher is the President of Biogen Inc, joining the firm since 2022.
What is the price performance of BIIB stock?
The current price of BIIB is $147.97, it has decreased 0.9% in the last trading day.
What are the primary business themes or industries for Biogen Inc?
Biogen Inc belongs to Biotechnology industry and the sector is Health Care
What is Biogen Inc market cap?
Biogen Inc's current market cap is $21.6B
Is Biogen Inc a buy, sell, or hold?
According to wall street analysts, 33 analysts have made analyst ratings for Biogen Inc, including 7 strong buy, 14 buy, 20 hold, 1 sell, and 7 strong sell
